Dr. John McDonald focuses his practice on planning and implementing international patent strategy for clients engaged in the biotechnology, pharmaceutical and chemical industries. He represents early stage, private and publicly traded companies. He regularly conducts intellectual property due diligence studies for clients including freedom to operate, validity and patentability opinions.
Dr. McDonald joined the faculty of the Department of Anatomy and Cell Biology at Emory University School of Medicine where he later became a tenured full professor. During his tenure at Emory, his research studies in peptide neuroendocrinology, neuroscience and endocrinology were funded by the National Institutes of Health, the National Science Foundation and the March of Dimes Birth Defects Foundation. He is currently an Emeritus Professor at Emory University School of Medicine. Dr. McDonald also conducted research studies in pancreatic endocrinology at the Marine Biological Laboratories in Woods Hole, Massachusetts, and in neurobiology at the Yerkes Regional Primate Research Center in Atlanta.
Dr. McDonald is listed in The Best Lawyers in America® in 2018 and each of the nine years immediately preceding. He was named a 2015 "Atlanta Lawyer of the Year" in the area of Biotechnology Law by The Best Lawyers in America®. Dr. McDonald is recognized as a Georgia "Super Lawyer" in the area of Intellectual Property in 2017 and the six years immediately preceding by Super Lawyers magazine. He received the Research Career Development Award from the National Institutes of Health. Dr. McDonald also received the Basil O'Connor Scholar Research Award from the March of Dimes Birth Defects Foundation as well as the Annual Basmajian/Williams & Wilkins Award for outstanding research and teaching from the American Association of Anatomists. He is AV® rated by Martindale-Hubbell.*
*CV, BV, and AV are registered certification marks of Reed Elsevier Properties, Inc., used in accordance with the Martindale-Hubbell certification procedure's standards and policies.
We manage the global IP portfolio for Novelis Inc., an $11.1 billion dollar company and the world’s largest rolled aluminum producer in terms of volume shipped. Novelis’ patent portfolio consists of more than 200 patent families. We coordinated the company’s global patent strategy, identified new foreign patent counsel, accelerated prosecution of applications throughout the world, and assisted in European patent oppositions. In addition to managing the company’s global IP portfolio, we are also working with Novelis on corporate matters, licensing, trade secrets, and federal grants.
Represents Eli Lilly and prosecutes their U.S. patents and foreign patents concerning antiviral vaccines.
Assisted lead counsel for the plaintiff, a leader in the development and manufacturing of porous plastic and porous fiber products, in patent infringement litigation. Soon after filing the suit, we filed a motion for preliminary injunction, engaged in expedited discovery and had a hearing date for an evidentiary hearing on the motion. At the same time the case was proceeding, our client was engaged in confidential negotiations for an asset sale transaction that included the operating business and the patent involved in the litigation that made the resolution of the case an important consideration in closing that transaction. Against that backdrop, we were able to negotiate a settlement of the lawsuit with the defendant on terms that pleased not only our client but the third party with which our client was negotiating and enabled our client to close its significant asset sale transaction.
Represents Telesta Therapeutics Inc., a pharmaceutical manufacturer, on intellectual property issues including design and implementation of global patent strategy, preparing and prosecuting patent applications and assisting in IP due diligence.
Assisted lead counsel in representing Biotest AG (Biotest), a German publicly traded biotechnology company, in signing a global License, Development and Commercialization Agreement with Abbott Laboratories for the further development and commercialization of Biotest’s BT-061, a novel anti-CD4 antibody for the treatment of Rheumatoid Arthritis (RA) and psoriasis. In connection with the deal, Biotest will receive an upfront payment of $85 million, and upon completion of certain milestones, additional payments totaling $395 million, plus royalties.
Advises Porex Corporation in developing and coordinating global patent strategy, preparing and prosecuting patent applications in the areas of medical devices, polymer chemistry and inorganic chemistry for medical implants, filters, nibs, detection devices and wicks, assisting in due diligence for intellectual property matters, and managing its trademark portfolio.
Represents ProteoVec LLC and coordinates their international patent strategy. The firm has prepared and prosecuted patent applications involving genetic manipulation of avians using transposon-based vectors to produce therapeutic proteins and antibodies in their eggs and in cell culture.
Georgia State University, College of Law, J.D. (1994)
University of Rochester, Ph.D. (1980)
University of Rochester, M.S. (1979)
Colgate University, B.A. (1974) magna cum laude, Phi Beta Kappa
U.S. Patent and Trademark Office (1998)
Center for Behavioral Neuroscience, National Science Foundation Interinstitutional Grant administered through Georgia State University, Former Member External Advisory Board and Former ProBono Counsel
The Endocrine Society, Emeritus Member
Georgia State University School of Law, Intellectual Property Society, Founder
State Bar of Georgia, Intellectual Property Section, Member
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.